Aeterna Zentaris Inc.
Allerdings hat das Seniorenmanagement bisher derart viel in den Sand gesetzt,
das man auch die Zopta Ergebnisse kritisch betrachten sollte.
Allerdings werden wir wahrscheinlich im laufenden Jahre einen Resplit von
5:1 oder 6:1 haben und einen EUR Kurs, der 20 % höher ist als jetzt.
Aktienkurs nach 1:5 Resplit = 2 $. Aktie sinkt danach um 25 % = 1,5 $
minus € Kursverlust = 1,20 $.
Wenn dann die Phase III erfolgreich war, gehts richtig hoch. Der Zulassungsantrag
bringt noch einen Schub. Ein KE folgt mit 15 Mio Aktien. Duirchfinanziert.
Wenn dann die anderen Produkte ihre Phasen beendet haben, gehts richtig ab.
Die große Unbekannte ist das beschissene Management. Alles alte Knacker, die
nur das KE-Rad-drehen kennen und sich das gut entlohnen lassen.
Die schauen mehr auf das Vorstandssalär als auf die klinischen Erfolge.
Ist aber auch nur meine Meinung.
Hänge nun mit einigen tausend 26% im Minus. Eigentlich wäre ich schon längst wieder raus gegangen, doch ein Freund von mir hatte sie noch etwas teurer gekauft und aus Solidarität bleibe ich investiert. Er glaubt immer noch, das die wieder steigen.
Ist sein zweiter Wert, den er gekauft hatte.
Erster war Pfeiffer Vacum mit der er einen guten Gewinn gemacht hatte.
Dann fand er diesen Wert und wir sind rein. Das war der größte Fehler seit Jahren.
Na den,.... Zum Glück sind all meine anderen Investitionen ordentlich im Plus, so das ich selbst einen Totalverlust mit 5000 Stücken locker verkraften kann, ohne das es mir die Hosen aus zieht.
Trotzdem, wir investieren, um zu gewinnen.
Werden wir hier professionell abezogen?
Investiere sonst nur in Werte mit fundamental guter Story & Zahlen & Aussichten.
Mal sehen, wo mich dieser Zock hin führt.
Daumen hoch für die scheiß Bumsbude !
AZ ist ein Bio und da gehts hoch wenn die klinischen Studien erfolgreich sind.
Und bei Krebs dauern die KS teilweise extrem lang. Aber Ende 2015 soll ja
die PIII fertig sein.
Eine ziemlich gute News heute, zwar keine für Top Raketen News dennoch gut und aktuell mit fast -5% zum Vortag.
Optionen
| Boardmail an "Limak" |
Wertpapier: Cosciens Biopharma Corp |
Hab mich jetzt noch nicht wirklich lange mit AE beschäftigt, vielleicht hat wer gut Links außer die selbst beweihräuchernde Homepage
Danke und gruss
Herb
Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.
By PR Newswire, May 07, 2015, 07:30:00 AM EDT
Vote up AAA
Aeterna Zentaris and Ascend Therapeutics® to join forces in selling EMD Serono's growth hormone deficiency therapy product
QUÉBEC CITY, May 7, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZ) and EMD Serono, Inc., the U.S. and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany, today announced the finalization of a promotional services agreement that will allow Aeterna Zentaris to promote Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the United States. Saizen® is a recombinant human Growth Hormone (r-hGH) registered in the U.S. for the treatment of growth hormone deficiency (GHD) in children and adults.
Under the agreement, Aeterna Zentaris will detail Saizen® to designated medical professionals, representing an important incremental field promotion activity in support of the product. Payment to Aeterna Zentaris will be based on new, eligible patient starts on Saizen® above an agreed-upon baseline. Aeterna Zentaris has subcontracted with Ascend Therapeutics®US, LLC, with whom it previously established a co-promotion agreement that is currently underway, to detail Saizen® in territories not covered by Aeterna Zentaris. Financial terms of the agreement were not disclosed.
Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented on the agreement: "In collaboration with Ascend Therapeutics, our combined 53 sales representatives are eager and poised to begin detailing Saizen®. We recognize the value of direct promotion in this category and we look forward to achieving increased market share and growth for Saizen® by significantly increasing the share-of-voice and impact in support of the product."
David A. Dodd, Chairman and Chief Executive Officer of Aeterna Zentaris stated regarding the promotional services agreement, "This agreement with EMD Serono, a leading US biopharmaceutical company, is another important step toward the transformation of Aeterna Zentaris into a commercially operating company. With its ongoing efforts in the development of electronic recombinant human growth hormone injection devices, EMD Serono is leading innovation in the field of growth hormones, and offers us with Saizen®, a perfect fit for our endocrinology portfolio we are developing and pursuing. We will continue to look for products that we can co-promote or in-license in our core areas of endocrinology and oncology as we build our portfolio and our commercial capabilities."
About Growth Hormone Deficiency (GHD)
Growth hormone deficiency occurs when the pituitary gland in the brain is unable to release or produce adequate amounts of growth hormone. In children, growth hormone deficiency causes slow growth, and without treatment, few will reach their full height potential as an adult.
It is estimated that the incidence of growth hormone deficiency in children is between one in 4,000 and one in 10,000. Non childhood related adult growth hormone deficiency can also be a significant problem which affects three in 10,000 each year. It is recognized as a specific clinical syndrome.
About Saizen® [somatropin (rDNA origin) for injection]
Saizen for Injection is a formulation of a recombinant human growth hormone (GH). In the U.S. Saizen lyophilized product in 5 mg and 8.8 mg strengths is registered for the treatment of appropriate patients with pediatric and adult growth hormone deficiency.
Important Risk Information
Saizen® should not be used in children and adults with a critical illness caused by certain types of heart or stomach surgery, serious injury or a sudden and severe breathing problem, cancer or other tumors, certain types of eye problems caused by diabetes or in children with Prader-Willi syndrome who are severely overweight or have a history of breathing problems including sleep apnea.
The most common side effects reported in clinical trials in children were local reactions at the injection site (such as pain, numbness, redness and swelling), hypothyroidism, low blood sugar, seizures or convulsions, worsening of skin psoriasis, or swelling associated with fluid retention. In adults, pain in joints, muscle pain, tingling and numbness, carpal tunnel syndrome, increased blood sugar or hyperglycemia.
Other possible side effects are return of tumor or cancerous growths, headaches, changes in vision, nausea, vomiting, or pancreatitis. In children, worsening of scoliosis or hip and knee pain.
For full prescribing information, please see www.saizenus.com.
About EMD Serono
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, is a leading US biopharmaceutical company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials - and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause Aeterna Zentaris's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of Aeterna Zentaris to efficiently commercialize one or more of its products or product candidates, the ability of Aeterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult Aeterna Zentaris' quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. Aeterna Zentaris does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.
Read more: http://www.nasdaq.com/press-release/...a-20150507-00420#ixzz3ZUFXnirX